Hanx Biopharmaceuticals (Wuhan) (HKG:3378) has begun an artificial intelligence-driven drug development collaboration with Switzerland-based TwinEdge Bioscience, according to a Thursday Hong Kong bourse filing.
The collaboration will use TwinEdge's artificial intelligence technology and digital twin models to support translational medicine research for Hanx's lead bispecific antibody candidate.
Shares of Hanx were up nearly 2% in Friday morning trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments